Oxytocin Acetate

Cyclic disulfide-bridged oxytocin research reference · acetate form must be confirmed by lot

Lot-specific chromatographic purity plus quantitative peptide content; confirm disulfide state, acetate/counterion, water and related peptides separately · target, verify batch COACAS 6233-83-6RUO

Research statusExtensive receptor, physiology and approved-finished-drug literature; bulk oxytocin acetate remains unapproved and for laboratory research only reference context · supplied material is RUO

Supplied formNonapeptide (cyclic, disulfide-bridged)

Lead time14–21 days

Oxytocin Acetate — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA

Oxytocin Acetate — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Defensible research value includes OXTR pharmacology, smooth-muscle and calcium-signalling models, receptor selectivity versus vasopressin receptors, neurobehavioural model design, disulfide-folding analytics and reference-standard qualification
Approved finished-drug efficacy cannot be transferred to bulk material, and “love hormone,” trust, autism, weight-loss or wellness claims are not established uses of this RUO lot.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 6233-83-6
Formula: C₄₃H₆₆N₁₂O₁₂S₂
Molecular weight: Approximately 1,007.19 Da
Appearance: Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA
Purity: Lot-specific chromatographic purity plus quantitative peptide content; confirm disulfide state, acetate/counterion, water and related peptides separately · target, verify batch COA
Storage: Follow the released-batch storage statement and SDS. Confirm post-opening or prepared-sample stability against the laboratory's validated protocol.
MOQ: On request
Lead time: 14–21 days

PubChem CID 439302

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Oxytocin Acetate

Oxytocin is a cyclic disulfide-bridged nonapeptide acting at the oxytocin receptor and, at some exposures, related vasopressin receptors. Named synthetic oxytocin injection finished drugs are approved for specific obstetric uses, while many intranasal social-cognition claims remain investigational and have produced mixed or negative trial results. Those approvals and studies do not make bulk oxytocin acetate an approved medicine. Lot qualification must resolve cyclic disulfide connectivity, peptide identity, acetate or other counterions and quantitative content.

Appropriate laboratory contexts include OXTR binding and signalling, receptor-selectivity studies, smooth-muscle and reproductive-tissue models, neurobehavioural models with rigorous controls, disulfide-folding and related-peptide analytics, and reference-standard work
Approved clinical indications belong to named finished drugs, not this bulk material.

Mechanism context

The question the literature is testing

Oxytocin activates OXTR-dependent G-protein and calcium signalling in appropriate models and can cross-react with vasopressin receptors depending on concentration and system. Central behavioural effects are context-dependent and not reducible to a universal bonding response. Correct intramolecular Cys1–Cys6 disulfide connectivity is central to the native cyclic structure; reduced, mispaired or intermolecular species must be analytically distinguished.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaHormonal research

Routes reported in sources

Intranasal

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary administration
Named finished-drug labels contain serious obstetric, haemodynamic and water-intoxication warnings that require clinical monitoring; they do not establish safety of bulk RUO material
Incorrect disulfide state, content or counterion, degradation, aggregation, contamination and unvalidated endotoxin or sterility are material research risks.

Interactions reported in the literature

No human combination guidance applies
SSRI, benzodiazepine, alcohol, selank, PT-141 and kisspeptin combination claims were removed from the RUO decision content
Laboratory receptor cross-reactivity or combination studies require defined systems, single-agent controls and concentration matrices.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Oxytocin Acetate factory batch COAs

Oxytocin Acetate 2 mg Factory batch COA protected preview

Oxytocin Acetate2 mg · WHJLP-OXYT2-260626-D

Oxytocin Acetate 5 mg Factory batch COA protected preview

Oxytocin Acetate5 mg · WHJLP-OT5-260626-D

Oxytocin Acetate 10 mg Factory batch COA protected preview

Oxytocin Acetate10 mg · WHJLP-OT10-260625-D

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require sequence and Cys1–Cys6 disulfide-connectivity evidence, intact mass, peptide mapping where appropriate, chromatographic purity and related peptides, quantitative peptide content on a stated basis, acetate and other counterions, water, residual solvents, reduction or oxidation products, aggregation or particulates where relevant, container integrity and lot-specific stability
Appearance or a single HPLC result is insufficient.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

OT-02MG2 mg10 vials

OT-05MG5 mg10 vials

OT-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-batch storage statement and SDS. Confirm post-opening or prepared-sample stability against the laboratory's validated protocol.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Primary boundaries include the FDA Pitocin label for the named finished injection and its clinical warnings, NIH PubChem molecular identity records, and peer-reviewed receptor and clinical-trial literature. Finished-drug doses, storage and approved indications are evidence context only. Large intranasal social-cognition trials with negative primary endpoints prevent one-sided efficacy claims.

01
Oxytocin increases trust in humans
Nature · 2005 · peer-reviewed original research
Open source
02
Does oxytocin increase trust in humans? A critical review of research
Perspectives on Psychological Science · 2015 · critical review
Open source
03
The neurobiological impact of oxytocin in mental health disorders: a comprehensive review
Annals of Medicine and Surgery (London) · 2025 · comprehensive review
Open source
04
The effects of oxytocin administration on social and routinized behaviors in autism: A preregistered systematic review and meta-analysis
Psychoneuroendocrinology · 2024 · preregistered systematic review and meta-analysis
Open source
05
Optimal dose of oxytocin to improve social impairments and repetitive behaviors in autism spectrum disorders: meta-analysis and dose-response meta-analysis of randomized controlled trials
Frontiers in Psychiatry · 2025 · meta-analysis and dose-response meta-analysis
Open source
06
WHO Recommendations: Uterotonics for the Prevention of Postpartum Haemorrhage
World Health Organization (NCBI Bookshelf reproduction) · 2018 · regulatory/global health body recommendation
Open source
07
Oxytocin is an age-specific circulating hormone that is necessary for muscle maintenance and regeneration
Nature Communications · 2014 · peer-reviewed original research
Open source
08
Pitocin (Oxytocin Injection, USP) Prescribing Information
US Food and Drug Administration (accessdata.fda.gov) · 2021 · regulatory document (FDA drug label)
Open source

Product FAQ

Questions buyers ask about Oxytocin Acetate

Why is oxytocin’s disulfide state essential to identity testing?+

Oxytocin contains an intramolecular Cys1–Cys6 disulfide bridge that defines the cyclic peptide. Qualification should combine intact mass with a method that distinguishes oxidized cyclic material from reduced, mispaired or intermolecular-disulfide species, such as peptide mapping and a qualified chromatographic comparison. A nominal mass or HPLC area value alone does not prove correct disulfide connectivity.

How should free oxytocin and oxytocin acetate be reported?+

The peptide moiety, acetate or other counterions, water and assay basis must be separated. Formula C₄₃H₆₆N₁₂O₁₂S₂ and about 1007.19 Da describe the oxytocin peptide reference, while an acetate-containing material has additional counterion mass and potentially variable stoichiometry. The COA should state whether peptide content is reported as-is, anhydrous, free-peptide equivalent or salt.

What should a laboratory request beyond a purity percentage?+

Request sequence and disulfide-connectivity evidence, intact mass, peptide mapping where appropriate, chromatographic purity and related-peptide profile, quantitative peptide content, acetate and other counterions, water, residual solvents, oxidation or reduction products, aggregation or particulates where relevant, container integrity and lot-specific stability. Endotoxin, bioburden and sterility are separate study-dependent attributes.

Oxytocin Acetate

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Oxytocin Acetate

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Oxytocin Acetate factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Oxytocin increases trust in humans

Does oxytocin increase trust in humans? A critical review of research

The neurobiological impact of oxytocin in mental health disorders: a comprehensive review

The effects of oxytocin administration on social and routinized behaviors in autism: A preregistered systematic review and meta-analysis

Optimal dose of oxytocin to improve social impairments and repetitive behaviors in autism spectrum disorders: meta-analysis and dose-response meta-analysis of randomized controlled trials

WHO Recommendations: Uterotonics for the Prevention of Postpartum Haemorrhage

Oxytocin is an age-specific circulating hormone that is necessary for muscle maintenance and regeneration

Pitocin (Oxytocin Injection, USP) Prescribing Information

Questions buyers ask about Oxytocin Acetate

Compare adjacent molecules and documentation needs.

Kisspeptin-10

ACTH (1-39)

HCG

Menotropins (HMG)